There has been a seismic shift in public perception toward hallucinogenic drugs such as psilocybin in the past couple of years. After decades of criminalization and little to no research on the effects of psychedelics, the substances have seen a significant surge in interest among the scientific community.
Initial research has found that psychedelic drugs seem to have positive effects on mental health, especially when paired with psychotherapy. Researchers have found that psychedelic-assisted psychotherapy can alleviate the symptoms of mental health conditions including treatment-resistant depression, post-traumatic stress disorder (PTSD) and eating disorders.
Some have called it the psychedelic renaissance, stating that hallucinogenic drugs have the potential to revolutionize psychiatry as we know it. In an upcoming documentary from ALTRD.TV, leading industry experts will discuss the resurgence of psychedelic research and the impact hallucinogenic treatments are expected to have on psychiatry. The documentary, titled “Open Minds; Exploring Psychedelic Medicine,” will involve psychedelic experts from MAPS, the Chopra Foundation, Cybin Inc. and the Mckenna Academy of Natural Philosophy, among others.
The six-part miniseries will concentrate on the recent surge in psychedelic interest among the scientific community, the experience of undergoing psychedelic treatments, consciousness, and how mental healthcare will evolve and grow in the future.
Executive producer Joshua Otten stated that the documentary will explore many of the questions around the relatively new field of psychedelic-assisted mental health treatments. He explained that the makers of the documentary consulted with a variety of researchers, industry leaders and those who had used psychedelic treatments to present an accurate idea of the industry’s state.
Furthermore, Otten added, collaborating with all kinds of people allowed the documentary to paint a picture of both the future of psychedelic-assisted treatments and the past “we’ve come from.” He said that research into psychedelic treatments can have a “profound impact” on millions of people worldwide who desperately need new and innovative mental health treatments.
According to the World Health Organization, more than 970 million people across the world were living with mental illness by 2019. Depression affects an estimated 5% of adults globally and is the leading cause of disability in the world. While medications such as anti-depressants can be effective at alleviating depressive symptoms, they often come with a variety of side effects, including indigestion, appetite loss, insomnia, fatigue and problems with libido.
Psychedelic medication that can treat such conditions with none of the side effects could change the lives of innumerable people.
The documentary will feature industry experts including the Chopra Foundation founder, professor and author Dr. Deepak Chopra; interdisciplinary research veteran researcher, Dennis Mckenna; Kernel founder and CEO, Keith Ferrazzi; and Cybin Inc. CEO Bryan Johnson. It will also involve Christie Strongman, a psychedelics advocate and MDA psychotherapist and trainer at the Multidisciplinary Association for Psychedelic Studies (MAPS).
Strongman, who has worked with patients who benefited from groundbreaking MAPS research, said that the documentary will help raise awareness of alternative treatments for mental illnesses. This documentary offers a different way to disseminate information about psychedelics to complement what companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have been doing to raise public awareness.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
